Skip to content
naulon

Not checkedNot checked for notices yet.

Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy

Slotman Ben J, Rietveld Derek HF, Verbakel Wilko FAR and 2 more

Radiation Oncology · 2011

doi:10.1186/1748-717x-6-74 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<p>Abstract</p> <p>Background</p> <p>Salivary gland function decreases after radiation doses of 39 Gy or higher. Currently, submandibular glands are not routinely spared. We implemented a technique for sparing contralateral submandibular glands (CLSM) during contralateral elective neck irradiation without compromising PTV coverage.</p> <p>Methods</p> <p>Volumetric modulated arc therapy (RapidArc™) plans were applied in 31 patients with stage II-IV HNC without contralateral neck metastases, all of whom received elective treatment to contralateral nodal levels II-IV. Group 1 consisted of 21 patients undergoing concurrent chemo-radiotherapy, with elective nodal doses of 57.75 Gy (PTV<sub>elect</sub>) and 70 Gy to tumor and pathological nodes (PTV<sub>boost</sub>) in 7 weeks. Group 2 consisted of 10 patients treated with radiotherapy to 54.45 Gy to PTV<sub>elect </sub>and 70 Gy to PTV<sub>boost </sub>in 6 weeks. All clinical plans spared the CLSM using individually adapted constraints. For each patient, a second plan was retrospectively generated without CLSM constraints ('non-sparing plan').</p> <p>Results</p> <p>PTV coverage was similar for both plans, with 98.7% of PTV<sub>elect </sub>and 99.2% of PTV<sub>boost </sub>receiving ≥95% of the prescription dose. The mean CLSM dose in group 1 was 33.2 Gy for clinical plans, versus 50.6 Gy in 'non-sparing plans' (p < 0.001). In group 2, mean CLSM dose was 34.4 Gy for clinical plans, and 46.8 Gy for non-sparing plans (p = 0.002).</p> <p>Conclusions</p> <p>Elective radiotherapy to contralateral nodal levels II-IV using RapidArc consistently limited CLSM doses well below 39 Gy, without compromising PTV-coverage. Future studies will reveal if this extent of dose reduction can reduce patient symptoms.</p>

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.